secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001558370-23-017657
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix Q3 revenues from goods up 16% to $10.2M; net loss narrows to $1.9M
---------------------------------------------------------------------------

- Revenues from selling goods $10.2M (+16% YoY), driven by Elfabrio sales to Chiesi after FDA/EMA approvals.
- License and R&D service revenues fell 96% to $0.2M as extension studies transferred to Chiesi.
- Net loss improved to $1.9M ($0.03 basic EPS) vs $3.6M loss ($0.07 EPS) in Q3 2022.
- Cash and equivalents $41.0M; PRX-115 Phase I for gout enrolled 32 patients, results expected mid-2024.
- Regulatory: UK MHRA and Swissmedic approved Elfabrio; Dr. Eliot Forster appointed Board Chairman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023017657/0001558370-23-017657-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023017657/plx-20231106x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-017657

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer